A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) as Third Line Treatment in Patients With Advanced Non-small Cell Lung Cancer (ALTER0302)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) as Third Line Treatment in Patients With Advanced Non-small Cell Lung Cancer (ALTER0302)

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2015

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ALTER0302; ALTN-NSCLC
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 27 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 22 Oct 2015 Planned End Date changed from 1 Jan 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
    • 22 Oct 2015 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top